Study Title
177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.
Study Details
Description:
Ga-68-FAPI has recently been proven to be superior to F-18-FDG in various cancers. These results have also raised hope in using FAP radiopharmaceuticals with theranostic approach. Lu-177 bound FAPI molecules have been started to be used in some cancers in clinical trials following its efficacy proven by case reports. Similarly,as a pilot study, this project aims to investigate safety and efficacy of Lu-177- FAP-2286 in metastatic urothelial carcinomas of bladder.
Sponsor:
Ankara University
Contacts:
Cigdem Soydal (Professor)csoydal@yahoo.com
+903125956732
Government Study Link:
NCT06880757 - Click here to see study onClinicalTrials.gov
Drug Details